Jarman E R, Hawrylowicz C M, Panagiotopolou E, O'Hehir R E, Lamb J R
Department of Immunology, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London.
J Allergy Clin Immunol. 1994 Nov;94(5):844-52. doi: 10.1016/0091-6749(94)90152-x.
Recent analysis of the usage of T-cell receptor (TcR) beta chain variable region (V beta) gene elements by house dust mite (HDM)-reactive T cells from an atopic donor suggested that TcR-V beta 3 gene products may form a major component of the human T-cell repertoire reactive to this common allergen. In this study a peptide analog of the TcR-V beta 3 complementarity determining region 2 (CDR2) is shown to inhibit the polyclonal human T-cell response to HDM; this effect is specific because inhibition is dependent on the presence of V beta 3 + T cells. This experimental approach has been used to determine whether the pattern seen in T-cell clones derived from one atopic donor reflects TcR-V beta usage in the polyclonal response to allergen in the general population. Inhibition of more than 50% of the polyclonal response to allergen by V beta 3-CDR2 peptide was observed in 16 of 21 donors tested, suggesting that TcR-V beta 3 gene usage may form a major component of the human HDM repertoire and as such offer a suitable target for T cell-directed specific immunotherapy in HDM-allergic individuals. Depletion of CD8+ T cells abolishes peptide-mediated inhibition of CD4+ T-cell proliferation to HDM, suggesting that induction of a CD8+ regulatory T-cell subset by the CDR2 peptide may modulate HDM-specific allergic T-cell responses.
最近对来自一位特应性供体的尘螨(HDM)反应性T细胞使用T细胞受体(TcR)β链可变区(Vβ)基因元件的分析表明,TcR-Vβ3基因产物可能构成人类对这种常见过敏原反应性T细胞库的主要成分。在本研究中,TcR-Vβ3互补决定区2(CDR2)的肽类似物被证明可抑制人类对HDM的多克隆T细胞反应;这种效应具有特异性,因为抑制作用依赖于Vβ3 + T细胞的存在。该实验方法已被用于确定从一位特应性供体获得的T细胞克隆中观察到的模式是否反映了普通人群中对过敏原多克隆反应中的TcR-Vβ使用情况。在21名受试供体中的16名中观察到Vβ3-CDR2肽对超过50%的过敏原多克隆反应有抑制作用,这表明TcR-Vβ3基因的使用可能构成人类HDM反应库的主要成分,因此为HDM过敏个体的T细胞定向特异性免疫治疗提供了一个合适的靶点。CD8 + T细胞的耗竭消除了肽介导的对HDM的CD4 + T细胞增殖抑制作用,这表明CDR2肽诱导的CD8 + 调节性T细胞亚群可能调节HDM特异性过敏T细胞反应。